Fundación para la Investigación del Hospital Clínico de Valencia

incliva.es

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

67

Active

15

Phase 3

3

Total enrollment

23,356

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Dapagliflozin2
Ferric Carboxymaltose Injection [Ferinject]1
Metformin1
Dulaglutide1
Semaglutide 1.0 mg1
Empagliflozin1
Canagliflozin1
pioglitazone1
Sitagliptin1
Vildagliptin1
linagliptin1
Sodium Zirconium Cyclosilicate2
Standard of care treatment1

Next readouts

  • 2025-07-30
  • 2025-12-01
  • 2026-06-30
  • 2026-12-30
  • 2028-04

Top conditions

  • Heart Failure8
  • Gastric Cancer4
  • Breast Cancer3
  • Lung Collapse3
  • Type 1 Diabetes3
  • Heart Failure With Preserved Ejection Fraction2
  • Magnetic Resonance2
  • Chronic Kidney Diseases2

Frequently asked questions about Fundación para la Investigación del Hospital Clínico de Valencia

How many clinical trials does Fundación para la Investigación del Hospital Clínico de Valencia have on ClinicalTrials.gov?
Fundación para la Investigación del Hospital Clínico de Valencia is listed as the lead sponsor on 67 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
How many of Fundación para la Investigación del Hospital Clínico de Valencia's trials are in Phase 3?
3 of Fundación para la Investigación del Hospital Clínico de Valencia's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does Fundación para la Investigación del Hospital Clínico de Valencia focus on?
Fundación para la Investigación del Hospital Clínico de Valencia's most-studied conditions on ClinicalTrials.gov are Heart Failure, Gastric Cancer, Breast Cancer, Lung Collapse, Type 1 Diabetes.
When are Fundación para la Investigación del Hospital Clínico de Valencia's next clinical trial readouts?
Fundación para la Investigación del Hospital Clínico de Valencia has 5 upcoming primary-completion readouts tracked here; the soonest is “Keeping RAASi Treatment With Optimal Potassium Control”, expected around 2025-07-30.